Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...
We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...
We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
4d
Zacks.com on MSNCRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on ItZacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report ...
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...
In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.
CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...
Samarth Kulkarni, the Chief Executive Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), recently sold a significant portion of his holdings in the company, according to a recent SEC filing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results